Phase II trial of motexafin gadolinium and docetaxel for second line treatment of patients with advanced non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Motexafin gadolinium (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Pharmacyclics
- 24 Oct 2013 According to ClinicalTrials.gov record, status changed from completed to discontinued.
- 19 Aug 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 13 Mar 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.